ECX — Epigenomics AG Share News
0.000.00%
Last trade - 00:00- €0.61m
- -€2.62m
- €0.49m
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns
Brief: Epigenomics AG Chief Executive Officer Greg Hamilton Resigns
Brief: Epigenomics AG Says Chief Executive Officer Greg Hamilton Is Resigning From Company And Executive Board Effective June 30, 2023
Brief: Epigenomics AG Expects Adj Ebitda In Range Of Eur ‑11.0 Mln To Eur ‑11.6 Mln For FY 22
Brief: Epigenomics Says Supervisory Board Chairman Heino Von Prondzynski Will Resign Effective March 31
Brief: Epigenomics Sees 2022 Revenue Between EUR 0.3 And EUR 0.8 Mln
Brief: Epigenomics: FY Revenue At EUR 6.2 Mln
Brief: Epigenomics Retains Greg Hamilton As CEO Through 2025
Brief: Epigenomics Appoints New CFO
Brief: Epigenomics Appoints Andrew Lukowiak As President And Chief Scientific Officer
Brief: Epigenomics 9-Mth Net Loss Narrows To EUR -691,000
Brief: Epigenomics Says EVP Of Finance Albert Weber Leaves Co
Brief: Epigenomics Places Mandatory Convertible Bonds Of Total EUR 16.5 Mln
Brief: Epigenomics Reduction Of Principal Amount Of Planned Mandatory Convertible Bond
Brief: Epigenomics AG Execution Of A Biobank Sale Agreement And Update Of Guidance
Brief: Epigenomics H1 EBITDA Loss At EUR -3.2 Mln